Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology (NYSE: MAIA) announced that the FDA has granted Rare Pediatric Disease Designation for THIO in treating pediatric-type diffuse high-grade gliomas (PDHGG). This designation makes MAIA eligible for a priority review voucher upon future FDA approval, which can be sold as an asset with an average value of $100 million since 2015.
Previous research demonstrated THIO's effectiveness when combined with ionizing radiation in treating diffuse intrinsic pontine glioma (DIPG), a PDHGG subtype, showing significant decrease in cell proliferation. THIO, believed to be the only direct telomere-targeting agent in clinical development, also holds orphan drug designations for hepatocellular carcinoma, small cell lung cancer, and glioblastoma.
MAIA Biotechnology (NYSE American: MAIA) has announced a private placement of 507,364 shares of common stock at $1.872 per share to accredited investors and company directors. Each share comes with a warrant to purchase one additional share at $2.08, exercisable after six months with a five-year term.
The placement is expected to raise approximately $950,000 in gross proceeds, closing around December 11, 2024. The funds will be used to manufacture THIO for Phase II clinical trials and working capital. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, and have not been registered under the Securities Act.
MAIA Biotechnology has expanded its 2021 clinical supply agreement with Regeneron for the Phase 2 THIO-101 trial. The expansion will evaluate THIO's efficacy when administered sequentially with Libtayo® (cemiplimab) in third-line non-small cell lung cancer (NSCLC) patients who were resistant to previous checkpoint inhibitor treatments and chemotherapy. Under the amended agreement, MAIA remains the trial sponsor while Regeneron will supply Libtayo® for all patients. The trial has shown promising results in disease control, progression-free survival, and overall response rates. MAIA plans to begin new patient enrollment soon and is exploring potential accelerated approval opportunities in the United States.
MAIA Biotechnology announced that independent director Stan V. Smith, Ph.D. purchased 100,000 shares of common stock and warrants to purchase an additional 100,000 shares for a total of $225,900 in the company's recent private placement. The transaction, announced on October 28, 2024, closed on November 1, 2024. Smith, one of MAIA's original investors, has participated in nearly every private placement financing round since the company's inception. As president of Smith Economics Group, , he expressed confidence in MAIA's THIO franchise's potential in treating multiple difficult-to-treat cancer types through telomere targeting and immunogenicity.
MAIA Biotechnology announced that its late-breaking abstract from the THIO-101 Phase 2 clinical trial has been selected for presentation at the 2024 SITC Annual Meeting. The presentation will showcase new efficacy and safety data for THIO combined with cemiplimab in advanced non-small cell lung cancer (NSCLC) patients who failed multiple standard treatments. As of August 1, 2024, 16 patients had survival follow-up exceeding 12 months, with 9 in third-line treatment showing interim median survival of 10.6 months, significantly surpassing the standard-of-care survival of 5.8 months.
MAIA Biotechnology (NYSE American: MAIA) has secured a $2.44 million private placement through the sale of 1,079,784 common stock shares at $2.259 per share to accredited investors and company directors. Each share comes with a warrant to purchase one additional share at $2.51, exercisable after six months with a five-year term. The proceeds will fund the manufacturing of THIO for the Phase 2 THIO-101 trial in non-small cell lung cancer (NSCLC) and working capital. The private placement is expected to close around October 30, 2024.
MAIA Biotechnology (NYSE American: MAIA) announced that an abstract on its second-generation telomere-targeting THIO prodrugs has been accepted for poster presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain (October 23-25, 2024). The presentation will showcase preclinical studies of MAIA-2021-20 and MAIA-2022-12, lipid-conjugated compounds derived from THIO, belonging to a new class called telomere targeting divalent dinucleotides.
The studies evaluated these compounds' efficacy alone and in combination with immune checkpoint-blocking antibodies. Results demonstrated high efficacy, ability to overcome immunotherapy resistance, and marked activity in advanced tumors, showing tumor growth inhibition in preclinical models of lung cancer, colorectal carcinoma, melanoma, and hepatocellular carcinoma. MAIA is actively working to advance these candidates toward clinical development.
MAIA Biotechnology (NYSE American: MAIA) has announced positive interim survival updates from its Phase 2 THIO-101 study for advanced non-small cell lung cancer (NSCLC). The study evaluates THIO, a telomere-targeting treatment, sequenced with Regeneron's immune checkpoint inhibitor cemiplimab (Libtayo®). Key highlights include:
- 16 patients surpassed 12-month survival follow-up
- Median survival follow-up in third-line treatment was 10.6 months
- THIO's survival benefit in third-line treatment surpasses comparable standard-of-care overall survival of 5.8 months
- Previous data showed 38% overall response rate and 88% disease control rate in third-line treatment
The company expects to release full efficacy results of THIO-101 this year.
MAIA Biotechnology (NYSE American: MAIA) will present new Phase 2 clinical trial data for its lead candidate THIO at the H.C. Wainwright 26th Annual Global Investment Conference in September 2024. The presentation will focus on the THIO-101 trial, which combines THIO with the immune checkpoint inhibitor cemiplimab for advanced non-small cell lung cancer (NSCLC) patients who have failed multiple standard treatments.
Key highlights include:
- Presentation scheduled for September 10, 2024, at 08:00 am ET
- Updates on response rates and survival follow-up
- THIO's mechanism as a telomere-targeting agent with direct DNA damage and immune response induction
- Exceptional efficacy demonstrated in NSCLC to date
- Long-term efficacy results expected before year-end
THIO-101 is anticipated to be the first completed clinical study of a telomere-targeting agent in cancer treatment.
MAIA Biotechnology (NYSE American: MAIA) has announced positive updates from its Phase 2 THIO-101 trial, evaluating THIO sequenced with cemiplimab in advanced non-small cell lung cancer (NSCLC) patients who failed multiple standard therapies. Key highlights include:
1. Six patients have continued treatment for over 12 months, completing up to 21 cycles.
2. The THIO-cemiplimab combination shows significantly lower toxicity compared to standard treatments.
3. Treatment longevity suggests safety, efficacy, and ongoing benefits of MAIA's novel telomere-targeting therapy.
4. Current second-line NSCLC treatments typically last 3-4 months, while THIO patients are showing much longer treatment durations.
These results indicate THIO's potential as a durable and effective treatment for advanced NSCLC patients with options.